Disclosed herein in present invention a co-crystal comprising Quercetin and L-Arginine characterized by PXRD and IR and Mass spectra.

The present invention provides a novel synergistic pharmaceutical co-crystal of Mesalamine or its pharmaceutically acceptable salts as API along with coformers such as alpha amino acids, flavones or nutraceuticals for the treatment of inflammatory bowel disease, Crohn"s disease, ulcerative colitis, indeterminate col...

The present invention discloses novel synergistic pharmaceutical co-crystals of Metformin or its pharmaceutically acceptable salts and oleoylethanolamide in fixed stoichiometric ratio at lower dosage, with improved residence time thereby increasing the bioavailability and efficacy, as anti- diabetic agent. The inven...

Disclosed herein is a synergistic pharmaceutical co-crystal composition of Metformin and at least one alpha amino acid(s). 13

Disclosed herein in the present invention is the co-crystal comprising Quercetin and Isoniazid characterized by characterized by PXRD and IR and Mass spectra useful for treating tuberculosis.